-
公开(公告)号：US20230063696A1
公开(公告)日：2023-03-02
申请号：US18045739
申请日：2022-10-11
申请人： INSULET CORPORATION
发明人： David NAZZARO , Ian MCLAUGHLIN , Daniel ALLIS , Simon KOZIN , Maureen MCCAFFREY
摘要： Systems and methods for monitoring an operational state and/or a fill status of a drug container of a drug delivery device are provided. The drug container can hold a liquid drug. A plunger can be positioned within the drug container. A drive system can advance the plunger to expel the liquid drug from the container. A monitoring system can detect a movement and/or a position of the plunger and/or any component coupled to the plunger. The detection can enable determination of an amount of liquid drug that has been expelled and/or an amount of liquid drug remaining in the drug container. Dosing rates, flow rates, and dosage completion can also be determined.
-
公开(公告)号：US11565039B2
公开(公告)日：2023-01-31
申请号：US16599729
申请日：2019-10-11
申请人： INSULET CORPORATION
发明人： Jason O'Connor , Joon Bok Lee , Ian McLaughlin , John D'Arco
摘要： A drug delivery device may include an Inertial Measurement Unit (IMU) is provided. The IMU may include an accelerometer, a magnetometer, or a gyroscope. Motion parameters may be detected when the drug delivery device is shipped, being prepared for activation for use, or during use. The IMU may provide data indicative of a rapid deceleration, such as when a package containing the drug delivery device is dropped, or some other physical event experienced by the drug delivery device. The drug delivery device may also include internal or external pressure sensors or a blood glucose sensor that may coordinate with the IMU to provide additional feedback regarding the status of the device or user. A controller of the drug delivery device may generate a response depending on the particular parameters being monitored or may change device operational parameters as a result of detected system events.
-
3.发明申请公开(公告)号：US20230001089A1
公开(公告)日：2023-01-05
申请号：US17848675
申请日：2022-06-24
申请人： INSULET CORPORATION
摘要： Exemplary embodiments account for differing needs of a user over the menstrual cycle of the user to better control the blood glucose concentration of the user. The exemplary embodiments may be realized in control systems for medicament delivery devices that deliver medicaments, such as medicaments that regulate blood glucose concentration levels. Examples of such medicaments that regulate blood glucose concentration levels include insulin, glucagon, and glucagon peptide-1 (GLP-1) agonists. The exemplary embodiments are able to better tailor the dosages of the medicament delivered to the user with the medicament delivery device to reduce the risk of hyperglycemia and hypoglycemia and help reduce blood glucose concentration excursions.
-
公开(公告)号：US20220379028A1
公开(公告)日：2022-12-01
申请号：US17818504
申请日：2022-08-09
申请人： INSULET CORPORATION
发明人： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR
摘要： Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.
-
公开(公告)号：USD971416S1
公开(公告)日：2022-11-29
申请号：US29738222
申请日：2020-06-16
申请人： Insulet Corporation
设计人： Bryan Choate , Amanda Callaghan , Bryan Dillon , David Clare
-
公开(公告)号：US20220293234A1
公开(公告)日：2022-09-15
申请号：US17691829
申请日：2022-03-10
申请人： Insulet Corporation
发明人： Joon Bok LEE , Eric BENJAMIN , Jason O'CONNOR , Yibin ZHENG
摘要： The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and/or persistence of glucose excursions relative to a target glucose level.
-
公开(公告)号：US20220288304A1
公开(公告)日：2022-09-15
申请号：US17674093
申请日：2022-02-17
申请人： Insulet Corporation
发明人： Soroush KAMRAVA , Steven CARDINALI , Ian QUINN
IPC分类号： A61M5/142
摘要： A novel embodiment of a pump system, for example, of the type that would be used in a wearable drug delivery system, comprises, in a preferred embodiment, a reservoir, a plunger, disposed within the reservoir and driven by a scissor mechanism connected to a drive mechanism through a linkage, such that a force imparted by the drive mechanism in causes the scissor mechanism to expand thereby causing the plunger move within the reservoir to force a liquid drug contained within the reservoir through a fluid port to a patient.
-
8.发明申请公开(公告)号：US20220288300A1
公开(公告)日：2022-09-15
申请号：US17330115
申请日：2021-05-25
申请人： Insulet Corporation
发明人： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Trang LY
摘要： The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).
-
公开(公告)号：US20220287633A1
公开(公告)日：2022-09-15
申请号：US17685937
申请日：2022-03-03
申请人： Insulet Corporation
发明人： Yibin ZHENG , Ashutosh ZADE , Joon Bok LEE
摘要： Disclosed are processes and techniques implementable by devices and a drug delivery system to maintain optimal drug delivery for a user according to a user's diabetes treatment plan. The disclosed techniques enable a drug delivery device that received an analyte measurement value from an analyte sensor during a prior cycle time to determine a present analyte measurement value has not been received during a present cycle time. A processor of the drug delivery device may, in response to the determination, initiate an action to obtain the present analyte measure value from another device or an estimate of the present analyte measurement value. Based on an outcome of the initiated action, the processor may calculate a dosage of the drug using the present analyte measurement value or information related to the present analyte measurement value. The drug delivery device may also be operable to output the calculated dosage of the drug.
-
公开(公告)号：US20220241503A1
公开(公告)日：2022-08-04
申请号：US17578716
申请日：2022-01-19
申请人： Insulet Corporation
发明人： Yibin ZHENG , Joon Bok LEE
摘要： The disclosed examples provide techniques and devices for determining a daily basal profile or an adjusted basal need for a drug based on a collection of data that is filtered and processed. A controller may be configured to evaluate a history of drug delivery in both basal and bolus dosages and generate a daily basal profile or an adjusted basal need that is a time dependent that may be used to schedule basal dosages of a drug that more closely addresses a user's drug needs over the course of a time period, such as a day, week or the like.
-
-
-
-
-
-
-
-
-
搜索结果
227 条记录 (耗时 0.028 秒)